A targeted GC-MS sterol and bile acid metabolomics platform also confirmed the potential role of intestinal bile acid metabolism in modulating simvastatin efficacy through effects on tissue transport [64], because a single nucleotide polymorphism (SNP) in the gene encoding a transporter in the liver and intestine (i.e., SLCO1B1 encoding OATP1B1) has been associated with both statin LDL-C lowering efficacy and risk of statin-associated myopathy [65,66]. This evidence concerns the gene SLCO1B1 and myopathy.